研究单位：[1]Ginkgopharma CO., LTD[2]Tongji Hospital Affiliated To Tongji Medical College Huazhong University Of Science And technology Wuhan, Hubei, China[3]Wuhan Medical Treatment Center Wuhan, Hubei, China[4]Wuxi No.5 People's Hospital Wuxi, Jiangsu, China[5]The Affiliated Hospital OF Xuzhou Medical University Xuzhou, Jiangsu, China[6]The first hospital of JILIN university. Changchun, Jilin, China, 130000[7]The First Affiliated Hospital Of Guangxi Medical University Guangxi, Nanning, China[8]First Hospital Of Shanxi Medical University Taiyuan, Shanxi, China[9]Traditional Chinese Medical Hospital Affiliated To Southwest Medical University Luzhou, Sichaun, China[10]Chengdu Public Health Medical Center Chendu, Sichuan, China[11]Sichuan Province General Hospital Chengdu, Sichuan, China[12]First Affiliated Hospital Of Xinjiang Medical University Ürümqi, Xinjiang, China[13]Traditional Chinese Medical Hospital Uygur Autonomous Region Ürümqi, Xinjiang, China[14]Huzhou Center Hospital Huzhou, Zhejiang, China[15]The Sixth People's Hospital Of Zhengzhou Zhengzhou, Henan, China[16]The First Hospital Of Hebei Medical University Shijiazhuang, Hebei, China[17]Affiliated Hospital Of Zunyi Medical University Zunyi, Guizhou, China[18]Liuzhou General Hospital Liuzhou, Guangxi Zhuang Autonomous Region, China[19]Chongqing Public Health Medical Center Chongqing, Chongqing, China[20]Beijing Ditan Hospital,Capital Medical University Beijing, Beijing, China[21]Beijing YouAn Hospital ,Capital Medical University Beijing, Beijing, China
研究目的：
This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir administered for 12 weeks in patients with Hepatitis C (HCV) genotype1. Efficacy was assessed by the rate of sustained viral response (SVR) 12 weeks after the discontinuation of therapy (SVR12).
